A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays

Journal of Immunological Methods

Volumn 260, Issue 1-2, 2002, Pages 157-172

  Currier, Jeffrey R ^a   Kuta, Ellen G ^a   Turk, Ellen ^a   Earhart, Lyndsay B ^b   Loomis Price, Larry ^a   Janetzki, Sylvia ^c   Ferrari, Guido ^b   Birx, Deborah L ^a   Cox, Josephine H ^a  

^a US Military HIV Research Program   (United States)

^b DUKE UNIVERSITY   (United States)

^c Zellnet Consulting Inc   (United States)

Author keywords

ELISPOT; Immunogenicity; Interferon ; Vaccine trials

Indexed keywords

CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A1 ANTIGEN; HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS ANTIGEN; VIRUS PROTEIN;

ALLELE; ANALYTIC METHOD; ANTIGEN EXPRESSION; ARTICLE; AUTOMATION; CELL KILLING; CELL STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ENZYME LINKED IMMUNOSPOT; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; INFLUENZA VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MONONUCLEAR CELL; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCIBILITY; STANDARDIZATION; T LYMPHOCYTE; TARGET CELL;

AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV ANTIGENS; HUMANS; IMMUNOSORBENT TECHNIQUES; LYMPHOCYTE ACTIVATION; QUALITY CONTROL;

CYTOMEGALOVIRUS; DNA VIRUSES; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA VIRUS; RNA VIRUSES;

EID: 0036469827     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(01)00535-X     Document Type: Article

References (49)

1. Field studies of cytotoxic T lymphocytes in Malaria infections: Implications for Malaria vaccine development
2. HLA class I nucleotide sequences
3. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines
4. Putative immunodominant human immunodeficiency virus-specific CD8+ T-cell responses cannot be predicted by major histocompatibility complex class I haplotype
5. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 phase II vaccine investigators
6. Conservation of T cell receptor usage by HLA B27-restricted influenza-specific cytotoxic T lymphocytes suggests a general pattern for antigen-specific major histocompatibility complex class I-restricted responses
7. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines
8. CD8 independence and specificity of cytotoxic T lymphocytes restricted by HLA-Aw68.1
9. HLA-A, -B, -DRB1, -DQA1 and -DQB1 polymorphism in Thais
10. AIDS vaccines show promise after years of frustration
11. Extensive alanine substitutions increase binding affinity of an influenza nucleoprotein peptide to HLA-Aw68 and do not abrogate peptide-specific CTL recognition
12. Accomplishing cellular immune assays for evaluation of vaccine efficacy in developing countries
13. Reverse ELISPOT assay for clonal analysis of cytokine production. Enumeration of gamma-interferon secreting cells
14. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population
15. HLA-A1 and HLA-A3 T cell epitopes derived from influenza virus proteins predicted from peptide binding motifs
16. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
17. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
18. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children
19. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays
20. Phenotype and frequency of cells secreting IL-2, IL-4, IL-6. IL-10, IFN and TNF-alpha in human peripheral blood
21. Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients
22. Detection and quantification of blood-derived CD8+ T lymphocytes secreting TNF-a in response to HLA-A2.1 binding melanoma and viral peptide antigens
23. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups
24. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study
25. Polymorphisms in HLA Class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines
26. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects
27. Immunization with HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
28. Cytotoxic T-lymphocytes against malaria and tuberculosis: From natural immunity to vaccine design
29. Rapid effector function in CD8+ memory T cells
30. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
31. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
32. Major histocompatibility complex genotype is associated with disease progression and virus load levels in a cohort of human immunodeficiency virus type 1-infected Caucasians and African Americans
33. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes
34. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization, and quantitation
35. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes
36. Cellular immune responses to HIV
37. HIV-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted, HIV-1 immunogen in complete Freund's adjuvant
38. Challenges and opportunities for the development of an AIDS vaccine
39. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
40. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
41. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: A four-centre comparative trial
42. Quantification of tumor-specific T lymphocytes with the ELISPOT assay
43. Prediction of an HLA B8-restricted influenza epitope by motif
44. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
45. Immunologic monitoring of clinical trials in patients with cancer: Technology versus common sense
46. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy
47. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL